Shares of Insulet Corporation (NASDAQ:PODD - Get Free Report) have been assigned an average rating of "Hold" from the twenty-five analysts that are currently covering the stock, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have assigned a buy rating to the company. The average twelve-month target price among brokerages that have updated their coverage on the stock in the last year is $185.04.
A number of research firms recently issued reports on PODD. BTIG Research lowered Insulet from a "buy" rating to a "neutral" rating in a research note on Thursday, August 6th. Benchmark cut their price target on Insulet from $250.00 to $185.00 and set a "buy" rating for the company in a report on Thursday, August 6th. Wall Street Zen raised Insulet from a "hold" rating to a "buy" rating in a research note on Saturday, November 7th. Barclays lifted their price objective on Insulet from $150.00 to $165.00 and gave the stock an "equal weight" rating in a research report on Friday, November 6th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Insulet from $152.00 to $170.00 and gave the company a "neutral" rating in a research note on Thursday, November 5th.
View Our Latest Stock Analysis on PODD
Insulet Stock Down 3.7%
PODD opened at $139.98 on Thursday. The business has a 50 day moving average price of $142.20 and a two-hundred day moving average price of $171.85. Insulet has a 52 week low of $126.40 and a 52 week high of $354.88. The company has a market cap of $9.71 billion, a PE ratio of 22.80, a P/E/G ratio of 1.11 and a beta of 1.06. The company has a quick ratio of 1.83, a current ratio of 2.51 and a debt-to-equity ratio of 0.60.
Insulet (NASDAQ:PODD - Get Free Report) last issued its earnings results on Wednesday, November 4th. The medical instruments supplier reported $1.99 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.59 by $0.40. Insulet had a return on equity of 31.76% and a net margin of 13.44%. The business had revenue of $842.00 million during the quarter, compared to the consensus estimate of $832.63 million. During the same period in the prior year, the business posted $1.24 EPS. The company's revenue for the quarter was up 19.2% on a year-over-year basis. As a group, research analysts anticipate that Insulet will post 6.76 EPS for the current year.
Hedge Funds Weigh In On Insulet
A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new position in shares of Insulet during the 2nd quarter worth $1,018,582,000. Arrowstreet Capital Limited Partnership grew its stake in Insulet by 462.7% during the first quarter. Arrowstreet Capital Limited Partnership now owns 1,229,928 shares of the medical instruments supplier's stock worth $258,088,000 after buying an additional 1,011,369 shares during the period. Soleus Capital Management L.P. raised its position in Insulet by 64.6% in the third quarter. Soleus Capital Management L.P. now owns 1,726,500 shares of the medical instruments supplier's stock valued at $225,256,000 after purchasing an additional 677,500 shares during the period. Man Group plc purchased a new stake in shares of Insulet during the second quarter valued at approximately $78,746,000. Finally, Bank of America Corp DE acquired a new stake in shares of Insulet during the second quarter valued at about $64,921,000.
About Insulet
(
Get Free Report)
Insulet Corporation is a medical device company focused on insulin delivery for people with diabetes. Founded in 2000, the company developed the Omnipod platform, which delivers insulin through a small, wearable pod without the tubing used by many traditional insulin pumps. Its products include Omnipod DASH and Omnipod 5, an automated insulin delivery system that can adjust insulin delivery based on glucose readings from compatible continuous glucose monitors. Insulet also provides related controllers, mobile app features, supplies and customer support.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Insulet, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insulet wasn't on the list.
While Insulet currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.